Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kyorin Poised to Weather Kipres Cliff with Consecutive Drug Launches: President
May 15, 2017
- Santen to Take Another Stab at US Market, Eyes Stand-Alone Sales Force
May 15, 2017
- Astellas Ditches ASP8273 as NSCLC Treatment
May 15, 2017
- Opdivo Drives Ono to Record Profits in FY2016
May 15, 2017
- No Plan for LLP Split-Off at This Point: Sumitomo Dainippon Chief
May 15, 2017
- Sumitomo Dainippon Scores Record Earnings on Latuda Boost
May 15, 2017
- Sales of 4 Japan Drug Majors Dip 3.7% on Stronger Yen, Price Cuts; Global Brands Solid
May 12, 2017
- Daiichi Sankyo Eclipses Takeda, Becomes Top Maker by Japan Ethical Drug Sales
May 12, 2017
- AZ Union Petitions Court to Adjudicate Labor Dispute, Claiming Unfair Demotions and Pay Cuts
May 12, 2017
- Mitsubishi Tanabe to Transfer Production of Medway to Outside Party
May 12, 2017
- Chugai Grants JW Pharmaceutical Marketing Rights for Emicizumab in South Korea
May 12, 2017
- Astellas, Univ. of Tokyo to Expand Research Collaboration on Rice-Based Oral Vaccine
May 12, 2017
- Baxalta Files Patent Infringement Lawsuit against Chugai over Development of Hemophilia A Treatment Emicizumab in US
May 12, 2017
- Mitsubishi Tanabe Eyes M&As for Post-Radicava Strategy in US: President
May 11, 2017
- There Could Be Discussions on Price Reviews for Add’l Indication-Driven Sales Growth: Weber
May 11, 2017
- Mitsubishi Tanabe Sees Bullish Simponi, but Sales Slightly Lower on Price Revision
May 11, 2017
- Shionogi Wants to Zero In on Innovative Drugs, Teshirogi says on LLP Transfer
May 11, 2017
- Shionogi Enjoys Rise in Japan Sales, Profits on HIV Royalty Revenue
May 11, 2017
- Eisai Plans Japan Filing for Lenvima’s HCC Indication in June: CEO
May 11, 2017
- Eisai’s Global Brands Brisk but Sales Slip on Forex, Drug Price Revision
May 11, 2017
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…